Skip to main content

Advertisement

Log in

Islet Cell Transplantion: Update on Current Clinical Trials

  • Pancreas Transplantation (D Axelrod, Section Editor)
  • Published:
Current Transplantation Reports Aims and scope Submit manuscript

Abstract

In the last 15 years, clinical islet transplantation has made the leap from experimental procedure to standard of care for a highly selective group of patients. Due to a risk/benefit calculation involving the required systemic immunosuppression, the procedure is only considered in patients with type 1 diabetes, complicated by severe hypoglycemia or end stage renal disease. In this review, we summarize current outcomes of the procedure and take a look at ongoing and future improvements and refinements of beta cell therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Geyelin HR et al. The use of insulin in juvenile diabetes. J Metab Research. 1922;2:767–91.

    CAS  Google Scholar 

  2. Mering J, Minkowski O. Diabetes mellitus nach Pankreasexstirpation. Archiv für Experimentelle Pathologie und Pharmakologie. 1890;26.

  3. Sutherland DE, Matas AJ, Najarian JS. Pancreas and islet transplantation. World journal of surgery. 1977;2:185–95.

    Article  CAS  PubMed  Google Scholar 

  4. Ricordi C, Lacy PE, Scharp DW. Automated islet isolation from human pancreas. Diabetes. 1989;38 Suppl 1:140–2.

    Article  PubMed  Google Scholar 

  5. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967;16:35–9.

    Article  CAS  PubMed  Google Scholar 

  6. Reckard CR, Ziegler MM, Barker CF. Physiological and immunological consequences of transplanting isolated pancreatic islets. Surgery. 1973;74:91–9.

    CAS  PubMed  Google Scholar 

  7. Najarian JS et al. Human islet transplantation: a preliminary report. Transplantation proceedings. 1977;9:233–6.

    CAS  PubMed  Google Scholar 

  8. Brendel MD et al. International islet transplant registry, newsletter #9. University Hospital Giessen. 2001;8. http://www.med.uni-giessen.de/itr/newsletter/no_9/news_9.pdf.

  9. Shapiro AM et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230–8.

    Article  CAS  PubMed  Google Scholar 

  10. Shapiro AM et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318–30.

    Article  CAS  PubMed  Google Scholar 

  11. Warnock GL et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation. 2008;86:1762–6.

    Article  PubMed  Google Scholar 

  12. Thompson DM et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation. 2011;91:373–8.

    Article  PubMed  Google Scholar 

  13. Steffes MW et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26:832–6.

    Article  PubMed  Google Scholar 

  14. Harlan DM et al. Current advances and travails in islet transplantation. Diabetes. 2009;58:2175–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Toso C et al. Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am J Transplant. 2008;8:701–6.

    Article  CAS  PubMed  Google Scholar 

  16. Saudek F et al. Magnetic resonance imaging of pancreatic islets transplanted into the liver in humans. Transplantation. 2010;90:1602–6.

    Article  PubMed  Google Scholar 

  17. Wang P et al. Immune rejection after pancreatic islet cell transplantation: in vivo dual contrast-enhanced MR imaging in a mouse model. Radiology. 2013;266:822–30.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kriz J et al. Detection of pancreatic islet allograft impairment in advance of functional failure using magnetic resonance imaging. Transpl Int. 2012;25:250–60.

    Article  CAS  PubMed  Google Scholar 

  19. Esposito A et al. Liver perfusion changes occurring during pancreatic islet engraftment: a dynamic contrast-enhanced magnetic resonance study. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2014;14:202–9.

    Article  CAS  Google Scholar 

  20. Eriksson O et al. Positron emission tomography in clinical islet transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009;9:2816–24.

    Article  CAS  Google Scholar 

  21. Eich T et al. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. The New England journal of medicine. 2007;356:2754–5.

    Article  CAS  PubMed  Google Scholar 

  22. Bennet W et al. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci. 2000;105:125–33.

    Article  CAS  PubMed  Google Scholar 

  23. Moberg L et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002;360:2039–45.

    Article  CAS  PubMed  Google Scholar 

  24. Barton FB et al. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care. 2012;35:1436–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Choudhary P et al. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care. 2015;38:1016–29.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Barton FB. CITR update. In: IPITA, IXA, CTS Joint Congress. Melbourne; 2015.

  27. Lindahl JP et al. In patients with type 1 diabetes simultaneous pancreas and kidney transplantation preserves long-term kidney graft ultrastructure and function better than transplantation of kidney alone. Diabetologia. 2014;57:2357–65.

    Article  CAS  PubMed  Google Scholar 

  28. Lehmann R et al. Glycemic control in simultaneous islet-kidney versus pancreas-kidney transplantation in type 1 diabetes: a prospective 13-year follow-up. Diabetes care. 2015;38:752–9.

    Article  CAS  PubMed  Google Scholar 

  29. Bellin MD et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant. 2012;12:1576–83. This trial demonstrated the impact of T cell depleting induction IS on outcome and increasing the chance for successful single donor islet transplantation.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Posselt AM et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010;10:1870–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Turgeon NA et al. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant. 2010;10:2082–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Qi M et al. Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience. Acta Diabetol. 2014;51:833–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Berman DM et al. Bioengineering the endocrine pancreas: intraomental islet transplantation within a biologic resorbable scaffold. Diabetes. 2016.

  34. Maffi P et al. Autologous pancreatic islet transplantation in human bone marrow. Diabetes. 2013;62:3523–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ludwig B et al. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci U S A. 2013;110:19054–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Ontario H. Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review. Ontario health technology assessment series. 2015;15:1–84.

    Google Scholar 

  37. Hering B, et al. Phase 3 trial of transplantation of human islets in type 1 diabetes mellitus complicated by severe hypoglycemia. Diabetes Care. 2016. doi:10.2337/dc15-1988. The results of this single-arm Phase 3 trial will be instrumental in obtaining licensure for a human islet product from the FDA which is required to fund future clinical allogeneic islet transplant procedures.

  38. Bartlett ST et al. Report from IPITA-TTS opinion leaders meeting on the future of beta-cell replacement. Transplantation. 2016;100 Suppl 2:S1–S44.

    Article  PubMed  PubMed Central  Google Scholar 

  39. O’Connell PJ et al. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013;13:1850–8.

    Article  Google Scholar 

  40. Shapiro AM et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. The New England journal of medicine. 2000;343:230–8.

    Article  CAS  PubMed  Google Scholar 

  41. Kessler L et al. Influence of islet transportation on pancreatic islet allotransplantation in type 1 diabetic patients within the Swiss-French GRAGIL network. Transplantation. 2004;77:1301–4.

    Article  PubMed  Google Scholar 

  42. Rydgard KJ et al. Procurement of human pancreases for islet isolation-the initiation of a Scandinavian collaborative network. Transplant Proc. 2001;33:2538.

    Article  CAS  PubMed  Google Scholar 

  43. Goss JA et al. Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center. Transplantation. 2004;77:462–6.

    Article  PubMed  Google Scholar 

  44. Khan A et al. Remote processing of pancreas can restore normal glucose homeostasis in autologous islet transplantation after traumatic whipple pancreatectomy: technical considerations. Cell Transplant. 2012;21:1261–7.

    Article  PubMed  Google Scholar 

  45. Kesseli SJ, Smith KA, Gardner TB. Total pancreatectomy with islet autologous transplantation: the cure for chronic pancreatitis? Clin Transl Gastroenterol. 2015;6, e73.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Tai DS et al. Autologous islet transplantation with remote islet isolation after pancreas resection for chronic pancreatitis. JAMA Surg. 2015;150:118–24.

    Article  PubMed  Google Scholar 

  47. Borot S et al. Impact of the number of infusions on 2-year results of islet-after-kidney transplantation in the GRAGIL network. Transplantation. 2011;92:1031–8.

    PubMed  Google Scholar 

  48. Lablanche S et al. Five-year metabolic, functional, and safety results of patients with type 1 diabetes transplanted with allogenic islets within the Swiss-French GRAGIL network. Diabetes Care. 2015;38:1714–22.

    Article  CAS  PubMed  Google Scholar 

  49. Doppenberg J, Engelse M, De Koning E. A novel, rapid, efficient, automated, pancreatic islet isolation technique. In: EPITA - European Pancreas and Islet transplantation association - 6th Winter symposium. Innsbruck: Poster Presentation; 2016. p. 14.

    Google Scholar 

  50. Moassesfar S et al. A comparative analysis of the safety, efficacy, and cost of islet versus pancreas transplantation in nonuremic patients with type 1 diabetes. Am J Transplant. 2016;16:518–26.

    Article  CAS  PubMed  Google Scholar 

  51. Scharp DW et al. The use of Ficoll in the preparation of viable islets of Langerhans from the rat pancreas. Transplantation. 1973;16:686–9.

    Article  CAS  PubMed  Google Scholar 

  52. Toso C et al. Histologic graft assessment after clinical islet transplantation. Transplantation. 2009;88:1286–93.

    Article  PubMed  Google Scholar 

  53. Bennet W et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes. 1999;48:1907–14.

    Article  CAS  PubMed  Google Scholar 

  54. Desai NM et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation. 2003;76:1623–5.

    Article  CAS  PubMed  Google Scholar 

  55. Pellegrini S et al. The state of the art of islet transplantation and cell therapy in type 1 diabetes. Acta Diabetol. 2016.

  56. Ciceri F, Piemonti L. Bone marrow and pancreatic islets: an old story with new perspectives. Cell Transplant. 2010;19:1511–22.

  57. Cantarelli E et al. Bone marrow as an alternative site for islet transplantation. Blood. 2009;114:4566–74.

  58. Ahearn AJ, Parekh JR, Posselt AM. Islet transplantation for type 1 diabetes: where are we now? Expert Rev Clin Immunol. 2015;11:59–68.

  59. Jacobs-Tulleneers-Thevissen D et al. Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia. 2013;56:1605–14.

  60. Fransson M et al. Mesenchymal stromal cells support endothelial cell interactions in an intramuscular islet transplantation model. Regen Med Res. 2015;3:1.

  61. Rickels MR et al. Improvement in beta-cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes. 2013;62:2890–7.

  62. Schulz TC et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One. 2012;7, e37004.

  63. Ludwig B et al. A novel device for islet transplantation providing immune protection and oxygen supply. Horm Metab Res. 2010;42:918–22.

    Article  CAS  PubMed  Google Scholar 

  64. Rafael E et al. Intramuscular autotransplantation of pancreatic islets in a 7-year-old child: a 2-year follow-up. Am J Transplant. 2008;8:458–62.

    Article  CAS  PubMed  Google Scholar 

  65. Wszola M et al. TransEndoscopic Gastric SubMucosa Islet Transplantation (eGSM-ITx) in pigs with streptozotocine induced diabetes—technical aspects of the procedure—preliminary report. Ann Transplant. 2009;14:45–50.

    PubMed  Google Scholar 

  66. Caiazzo R et al. Evaluation of alternative sites for islet transplantation in the minipig: interest and limits of the gastric submucosa. Transplant Proc. 2007;39:2620–3.

    Article  CAS  PubMed  Google Scholar 

  67. Motte E et al. Composition and function of macroencapsulated human embryonic stem cell-derived implants: comparison with clinical human islet cell grafts. Am J Physiol Endocrinol Metab. 2014;307:E838–46.

    Article  CAS  PubMed  Google Scholar 

  68. Kroon E et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008;26:443–52.

    Article  CAS  PubMed  Google Scholar 

  69. Lind M et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972–82.

    Article  PubMed  CAS  Google Scholar 

  70. Feltbower RG et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults. Diabetes Care. 2008;31:922–6.

    Article  PubMed  Google Scholar 

  71. Skrivarhaug T et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia. 2006;49:298–305.

    Article  CAS  PubMed  Google Scholar 

  72. McCoy RG et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35:1897–901.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Yeoh E et al. Interventions that restore awareness of hypoglycemia in adults with type 1 diabetes: a systematic review and meta-analysis. Diabetes Care. 2015;38:1592–609.

    Article  PubMed  Google Scholar 

  74. Byrne ML et al. Outcomes for adults with type 1 diabetes referred with severe hypoglycaemia and/or referred for islet transplantation to a specialist hypoglycaemia service. Horm Metab Res. 2015;47:9–15.

    CAS  PubMed  Google Scholar 

  75. Ly TT et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310:1240–7.

    Article  CAS  PubMed  Google Scholar 

  76. Bergenstal RM et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369:224–32.

    Article  CAS  PubMed  Google Scholar 

  77. American Diabetes A. Standards of medical care in diabetes—2016—5. Glycemic targets. Diabetes Care. 2016;39(1):S39–46.

    Article  Google Scholar 

  78. Hopkins D et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience. Diabetes Care. 2012;35:1638–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Weinstock RS et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D exchange clinic registry. J Clin Endocrinol Metab. 2013;98:3411–9.

    Article  CAS  PubMed  Google Scholar 

  80. Miller KM et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care. 2015;38:971–8.

    Article  PubMed  Google Scholar 

  81. Cryer PE. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes. 2014;63:2188–95.

    Article  PubMed  Google Scholar 

  82. Brennan DC et al. Long-term follow-up of the Edmonton protocol of islet transplantation in the United States. Am J Transplant. 2016;16:509–17.

    Article  CAS  PubMed  Google Scholar 

  83. Radosevich DM et al. Comprehensive health assessment and five-yr follow-up of allogeneic islet transplant recipients. Clinical transplantation. 2013;27:24.

    Article  Google Scholar 

  84. Benhamou PY, Milliat‐Guittard L. Quality of life after islet transplantation: data from the GRAGIL 1 and 2 trials. 2009.

    Google Scholar 

  85. Snoek FJ et al. Monitoring of individual needs in diabetes (MIND)-2: follow-up data from the cross-national diabetes attitudes, wishes, and needs (DAWN) MIND study. Diabetes Care. 2012;35:2128–32.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Joensen LE, Tapager I, Willaing I. Diabetes distress in type 1 diabetes—a new measurement fit for purpose. Diabet Med. 2013;30:1132–9.

    Article  CAS  PubMed  Google Scholar 

  87. Trief PM et al. Depression in adults in the T1D exchange clinic registry. Diabetes Care. 2014;37:1563–72.

    Article  PubMed  Google Scholar 

  88. Nefs G et al. Fear of hypoglycaemia in adults with type 1 diabetes: results from diabetes MILES—the Netherlands. Diabet Med. 2015;32:1289–96.

    Article  CAS  PubMed  Google Scholar 

  89. Farney AC, Sutherland DE, Opara EC. Evolution of islet transplantation for the last 30 years. Pancreas. 2016;45:8–20.

    Article  PubMed  Google Scholar 

  90. Frank AM, Barker CF, Markmann JF. Comparison of whole organ pancreas and isolated islet transplantation for type 1 diabetes. Adv Surg. 2005;39:137–63.

    Article  PubMed  Google Scholar 

  91. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the international pancreas transplant registry (IPTR). Rev Diabet Stud. 2011;8:6–16.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Gruessner AC, Gruessner RW. Pancreas transplantation of US and non-US cases from 2005 to 2014 as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud. 2016. doi:10.1900/RDS.2016.13.e2016002.

  93. Niclauss N, Morel P, Berney T. Has the gap between pancreas and islet transplantation closed? Transplantation. 2014.

    Google Scholar 

  94. Kempf MC et al. Logistics and transplant coordination activity in the GRAGIL Swiss-French multicenter network of islet transplantation. Transplantation. 2005;79:1200–5.

    Article  PubMed  Google Scholar 

  95. Guignard AP et al. Cost analysis of human islet transplantation for the treatment of type 1 diabetes in the Swiss-French Consortium GRAGIL. Diabetes Care. 2004;27:895–900.

    Article  PubMed  Google Scholar 

  96. Gerber PA et al. Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia. 2008;51:110–9.

    Article  CAS  PubMed  Google Scholar 

  97. Hillberg AL et al. Improving alginate-poly-L-ornithine-alginate capsule biocompatibility through genipin crosslinking. J Biomed Mater Res B Appl Biomater. 2013;101:258–68.

    Article  PubMed  CAS  Google Scholar 

  98. Elliott RB, Living Cell T. Towards xenotransplantation of pig islets in the clinic. Curr Opin Organ Transplant. 2011;16:195–200.

    Article  CAS  PubMed  Google Scholar 

  99. Hudson A et al. The UK pancreas allocation scheme for whole organ and islet transplantation. Am J Transplant. 2015;15:2443–55.

    Article  CAS  PubMed  Google Scholar 

  100. Collett D et al. Organ allocation in the United Kingdom. Clin Transpl. 2010;53–60.

  101. Pepper AR et al. Diabetes is reversed in a murine model by marginal mass syngeneic islet transplantation using a subcutaneous cell pouch device. Transplantation. 2015;99:2294–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Pepper AR et al. A prevascularized subcutaneous device-less site for islet and cellular transplantation. Nat Biotechnol. 2015;33:518–23.

    Article  CAS  PubMed  Google Scholar 

  103. Shapiro AM. State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diab Rep. 2011;11:345–54.

    Article  PubMed  Google Scholar 

  104. Lei J et al. Pilot study evaluating regulatory T cell-promoting immunosuppression and nonimmunogenic donor antigen delivery in a nonhuman primate islet allotransplantation model. Am J Transplant. 2015;15:2739–49.

    Article  CAS  PubMed  Google Scholar 

  105. Kawai T et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358:353–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Kawai T et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant. 2014;14:1599–611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Szot GL et al. Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm. Cell Stem Cell. 2015;16:148–57.

    Article  CAS  PubMed  Google Scholar 

  108. Pagliuca FW et al. Generation of functional human pancreatic beta cells in vitro. Cell. 2014;159:428–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Pagliuca FW, Melton DA. How to make a functional beta-cell. Development. 2013;140:2472–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Rezania A et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014;32:1121–33.

    Article  CAS  PubMed  Google Scholar 

  111. Bruin JE, Rezania A, Kieffer TJ. Replacing and safeguarding pancreatic beta cells for diabetes. Sci Transl Med. 2015;7:316ps23.

    Article  PubMed  CAS  Google Scholar 

  112. Agulnick AD et al. Insulin-producing endocrine cells differentiated in vitro from human embryonic stem cells function in macroencapsulation devices in vivo. Stem cells translational medicine. 2015;4:1214–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Ricordi C, Edlund H. Toward a renewable source of pancreatic beta-cells. Nat Biotechnol. 2008;26:397–8.

    Article  CAS  PubMed  Google Scholar 

  114. Schuetz C, Markmann JF. Immunogenicity of beta-cells for autologous transplantation in type 1 diabetes. Pharmacol Res. 2015;98:60–8.

    Article  CAS  PubMed  Google Scholar 

  115. de Almeida PE et al. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat Commun. 2014;5:3903.

    PubMed  PubMed Central  Google Scholar 

  116. Ekser B et al. Clinical xenotransplantation: the next medical revolution? Lancet. 2012;379:672–83.

    Article  PubMed  Google Scholar 

  117. Hering BJ et al. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—executive summary. Xenotransplantation. 2016.

  118. Matsumoto S et al. Clinical porcine islet xenotransplantation under comprehensive regulation. Transplant Proc. 2014;46:1992–5.

    Article  CAS  PubMed  Google Scholar 

  119. Yang L et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science. 2015;350:1101–4.

    Article  CAS  PubMed  Google Scholar 

  120. Whitworth KM et al. Gene-edited pigs are protected from porcine reproductive and respiratory syndrome virus. Nat Biotechnol. 2016;34:20–2.

    Article  CAS  PubMed  Google Scholar 

  121. Salomon DR. A CRISPR way to block PERVs—engineering organs for transplantation. N Engl J Med. 2016;374:1089–91.

    Article  PubMed  Google Scholar 

  122. Perkel JM. Xenotransplantation makes a comeback. Nat Biotechnol. 2016;34:3–4.

    Article  CAS  PubMed  Google Scholar 

  123. Editorial. Xenotransplantation 2.0. Nat Biotechnol. 2016;34:1.

    Article  CAS  Google Scholar 

  124. Cowan PJ et al. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 2b: Genetically Modified Source Pigs. Xenotransplantation. 2016.

  125. Blau JE et al. Long-term immunosuppression after solitary islet transplantation is associated with preserved C-peptide secretion for more than a decade. Am J Transplant. 2015;15:2995–3001.

    Article  CAS  PubMed  Google Scholar 

  126. Berney T et al. Long-term insulin-independence after allogeneic islet transplantation for type 1 diabetes: over the 10-year mark. Am J Transplant. 2009;9:419–23.

    Article  CAS  PubMed  Google Scholar 

  127. Muller YD et al. Transplanted human pancreatic islets after long-term insulin independence. Am J Transplant. 2013;13:1093–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christian Schuetz.

Ethics declarations

Conflict of Interest

Christian Schuetz and James Markmann declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Pancreas Transplantation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schuetz, C., Markmann, J.F. Islet Cell Transplantion: Update on Current Clinical Trials. Curr Transpl Rep 3, 254–263 (2016). https://doi.org/10.1007/s40472-016-0103-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40472-016-0103-z

Keywords

Navigation